Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY LAWRENCE FREILICH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1659424810
CMS profile
29968
Location
KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,483.13

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,233.13 57
Honoraria $750.00 1
Consulting Fee $500.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY LAWRENCE FREILICH

NPI 1659424810 · CMS profile ID 29968

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY LAWRENCE FREILICH, NPI 1659424810, CMS profile ID 29968. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRADLEY LAWRENCE FREILICH, NPI 1659424810, CMS profile ID 29968. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRADLEY LAWRENCE FREILICH, NPI 1659424810, CMS profile ID 29968, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659424810?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $2,483.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $10.5502/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811289775 CMS
Novo Nordisk Inc $4.4502/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810927977 CMS
Nestle HealthCare Nutrition Inc. $21.2102/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820896549 CMS
AbbVie Inc. $13.2802/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794513967 CMS
Janssen Biotech, Inc. $15.3402/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788531189 CMS
AbbVie Inc. $12.3001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794513963 CMS
Intercept Pharmaceuticals, Inc. $750.0001/20/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836206151 CMS
Ironwood Pharmaceuticals, Inc $11.7101/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855121821 CMS
Intercept Pharmaceuticals, Inc. $10.1201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836206149 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,111.21 79
PY2020 $3,230.35 16
PY2021 $2,483.13 59
PY2022 $5,815.52 43
PY2023 $4,502.63 59
PY2024 $2,094.09 43
PY2025 $1,481.07 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,244,964.12 299
PY2024 Recipient $4,186.63 2
PY2024 Principal investigator $704,281.35 220
PY2023 Recipient $1,257.17 1
PY2023 Principal investigator $575,605.58 68
PY2022 Principal investigator $481,663.25 45
PY2021 Principal investigator $439,962.90 230
PY2020 Principal investigator $314,704.54 55
PY2019 Principal investigator $693,990.66 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

299 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 12/31/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870475
Principal investigator 1 Boehringer Ingelheim International GmbH $754.73 12/22/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654304
Principal investigator 1 Boehringer Ingelheim International GmbH $754.73 12/22/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654316
Principal investigator 1 Madrigal Pharmaceuticals $4,565.22 12/19/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254311
Principal investigator 1 Tanabe Pharma America, Inc. $2,176.20 12/19/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870381
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291696
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291698
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291700
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291702
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291706
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291708
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291710
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291712
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291714
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291716
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291718
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291720
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291722
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291724
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291726
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291728
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291730
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291732
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291734
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291736
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291738
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291740
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291742
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291744
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291746
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291748
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291750
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291752
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291754
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291756
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291758
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291760
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291762
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291764
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291766
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291768
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291770
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291772
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291774
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291776
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291778
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291780
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291782
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291784
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291786
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291788
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291790
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291792
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291794
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291796
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291798
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291800
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291802
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291804
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291806
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291808
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291810
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291830
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291832
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291834
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291836
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291838
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291840
Principal investigator 1 Seqirus USA Inc $847.00 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291842
Principal investigator 1 Seqirus USA Inc $422.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291844
Principal investigator 1 Seqirus USA Inc $422.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291846
Principal investigator 1 Seqirus USA Inc $422.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291848
Principal investigator 1 Seqirus USA Inc $422.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291850
Principal investigator 1 Seqirus USA Inc $422.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291852
Principal investigator 1 Seqirus USA Inc $422.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291858
Principal investigator 1 Seqirus USA Inc $847.00 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291860
Principal investigator 1 Seqirus USA Inc $1,108.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291865
Principal investigator 1 Seqirus USA Inc $1,162.00 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291868
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291878
Principal investigator 1 Seqirus USA Inc $1,108.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291934
Principal investigator 1 Seqirus USA Inc $1,108.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291936
Principal investigator 1 Seqirus USA Inc $1,108.80 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291938
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291940
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291942
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291944
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291946
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291948
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291950
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291952
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291954
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291956
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291958
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291960
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291962
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291964
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291966
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291968
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291970
Principal investigator 1 Seqirus USA Inc $3,204.60 12/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291972
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654336
Principal investigator 1 Boehringer Ingelheim International GmbH $479.52 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654338
Principal investigator 1 Boehringer Ingelheim International GmbH $1,460.00 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654340
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654342
Principal investigator 1 Boehringer Ingelheim International GmbH $375.00 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654362
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654366
Principal investigator 1 Boehringer Ingelheim International GmbH $439.56 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654368
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654370
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 12/17/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654372
Principal investigator 1 Madrigal Pharmaceuticals $10,001.60 12/11/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253842
Principal investigator 1 Madrigal Pharmaceuticals $11,664.00 12/05/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253566
Principal investigator 1 Boehringer Ingelheim International GmbH $39.76 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654288
Principal investigator 1 Boehringer Ingelheim International GmbH $99.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654290
Principal investigator 1 Boehringer Ingelheim International GmbH $1,400.00 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654292
Principal investigator 1 Boehringer Ingelheim International GmbH $71.00 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654294
Principal investigator 1 Boehringer Ingelheim International GmbH $170.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654296
Principal investigator 1 Boehringer Ingelheim International GmbH $134.90 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654298
Principal investigator 1 Boehringer Ingelheim International GmbH $170.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654300
Principal investigator 1 Boehringer Ingelheim International GmbH $106.50 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654302
Principal investigator 1 Boehringer Ingelheim International GmbH $170.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654306
Principal investigator 1 Boehringer Ingelheim International GmbH $284.00 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654308
Principal investigator 1 Boehringer Ingelheim International GmbH $92.30 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654310
Principal investigator 1 Boehringer Ingelheim International GmbH $134.90 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654312
Principal investigator 1 Boehringer Ingelheim International GmbH $106.50 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654314
Principal investigator 1 Boehringer Ingelheim International GmbH $170.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654318
Principal investigator 1 Boehringer Ingelheim International GmbH $6,973.77 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654320
Principal investigator 1 Boehringer Ingelheim International GmbH $170.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654322
Principal investigator 1 Boehringer Ingelheim International GmbH $284.00 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654324
Principal investigator 1 Boehringer Ingelheim International GmbH $170.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654326
Principal investigator 1 Boehringer Ingelheim International GmbH $99.40 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654328
Principal investigator 1 Boehringer Ingelheim International GmbH $1,604.52 12/03/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654364
Principal investigator 1 Seqirus USA Inc $4,701.40 12/01/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810394
Principal investigator 1 Seqirus USA Inc $1,291.95 12/01/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810403
Principal investigator 1 Boehringer Ingelheim International GmbH $754.73 11/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654278
Principal investigator 1 Boehringer Ingelheim International GmbH $2,578.72 11/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654280
Principal investigator 1 Boehringer Ingelheim International GmbH $754.73 11/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654282
Principal investigator 1 Boehringer Ingelheim International GmbH $3,687.74 11/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654284
Principal investigator 1 Boehringer Ingelheim International GmbH $13,467.28 11/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654286
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 11/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654360
Principal investigator 1 Madrigal Pharmaceuticals $16,631.64 11/25/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252870
Principal investigator 1 Madrigal Pharmaceuticals $6,194.46 11/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252420
Principal investigator 1 Seqirus USA Inc $3,846.60 11/03/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810381
Principal investigator 1 Seqirus USA Inc $1,057.05 11/03/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810388
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 11/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870483
Principal investigator 1 Boehringer Ingelheim International GmbH $1,400.00 10/29/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654272
Principal investigator 1 Boehringer Ingelheim International GmbH $3,687.74 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654268
Principal investigator 1 Boehringer Ingelheim International GmbH $3,687.74 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654270
Principal investigator 1 Boehringer Ingelheim International GmbH $13,467.28 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654274
Principal investigator 1 Boehringer Ingelheim International GmbH $754.73 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654276
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654330
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654332
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654334
Principal investigator 1 Seqirus USA Inc $1,500.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291870
Principal investigator 1 Seqirus USA Inc $2,000.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291872
Principal investigator 1 Seqirus USA Inc $2,500.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291874
Principal investigator 1 Seqirus USA Inc $3,000.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291876
Principal investigator 1 Seqirus USA Inc $12,000.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291880
Principal investigator 1 Seqirus USA Inc $2,000.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291930
Principal investigator 1 Seqirus USA Inc $2,000.00 10/27/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291932
Principal investigator 1 Madrigal Pharmaceuticals $900.00 10/23/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251799
Principal investigator 1 Madrigal Pharmaceuticals $70,245.00 10/23/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251803
Principal investigator 1 Madrigal Pharmaceuticals $3,350.00 10/23/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251807
Principal investigator 1 Madrigal Pharmaceuticals $1,100.00 10/23/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251811
Principal investigator 1 Madrigal Pharmaceuticals $5,000.80 10/23/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251816
Principal investigator 1 Gilead Sciences, Inc. $1,421.00 10/21/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207078
Principal investigator 1 Madrigal Pharmaceuticals $2,064.82 10/16/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251521
Principal investigator 1 Gilead Sciences, Inc. $3,310.32 10/14/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207067
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 10/09/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251419
Principal investigator 1 Tanabe Pharma America, Inc. $3,573.93 10/09/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870399
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 10/03/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251005
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 10/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870485
Principal investigator 1 Boehringer Ingelheim International GmbH $13,467.28 09/26/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654266
Principal investigator 1 Bausch Health US, LLC $2,272.82 09/24/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842247
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 09/24/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654262
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 09/24/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654264
Principal investigator 1 Madrigal Pharmaceuticals $4,129.64 09/18/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250225
Principal investigator 1 Seqirus USA Inc $110.98 09/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291854
Principal investigator 1 Seqirus USA Inc $111.30 09/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291856
Principal investigator 1 Seqirus USA Inc $946.80 09/18/2025 Non-covered Recipient Entity
Kansas City Research Institute LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291862
Principal investigator 1 Gilead Sciences, Inc. $7,954.13 09/16/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207059
Principal investigator 1 Madrigal Pharmaceuticals $2,064.82 09/12/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249900
Principal investigator 1 Bausch Health US, LLC $2,009.70 09/11/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842250
Principal investigator 1 Madrigal Pharmaceuticals $506.25 09/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249508
Principal investigator 1 Madrigal Pharmaceuticals $135.00 09/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249511
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 09/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249515
Principal investigator 1 Tanabe Pharma America, Inc. $140.00 09/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870401
Principal investigator 1 Tanabe Pharma America, Inc. $500.00 09/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870403
Principal investigator 1 Gilead Sciences, Inc. $975.66 09/02/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207048
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 09/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870487
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654258
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 08/26/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654260
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654358
Principal investigator 1 Madrigal Pharmaceuticals $4,129.64 08/26/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249082
Principal investigator 1 Madrigal Pharmaceuticals $2,064.82 08/21/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248866
Principal investigator 1 Tanabe Pharma America, Inc. $2,360.70 08/21/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870379
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 08/14/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248412
Principal investigator 1 Bausch Health US, LLC $2,031.12 08/08/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842255
Principal investigator 1 Madrigal Pharmaceuticals $2,064.82 08/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248115
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 08/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870473
Principal investigator 1 Madrigal Pharmaceuticals $40,941.00 07/31/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247741
Principal investigator 1 Madrigal Pharmaceuticals $1,100.00 07/31/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247745
Principal investigator 1 Madrigal Pharmaceuticals $16,007.62 07/31/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247749
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 07/31/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247753
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 07/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654256
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654354
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654356
Principal investigator 1 Madrigal Pharmaceuticals $6,194.46 07/22/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247398
Principal investigator 1 Tanabe Pharma America, Inc. $37.66 07/22/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870385
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 07/17/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247143
Principal investigator 1 Bausch Health US, LLC $2,320.29 07/09/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842243
Principal investigator 1 Madrigal Pharmaceuticals $1,356.00 07/08/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246658
Principal investigator 1 Madrigal Pharmaceuticals $607.50 07/08/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246661
Principal investigator 1 Madrigal Pharmaceuticals $708.75 07/08/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246666
Principal investigator 1 Madrigal Pharmaceuticals $1,821.75 07/08/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246670
Principal investigator 1 Madrigal Pharmaceuticals $506.25 07/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246600
Principal investigator 1 Madrigal Pharmaceuticals $14,227.50 07/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246605
Principal investigator 1 Madrigal Pharmaceuticals $1,000.00 07/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246609
Principal investigator 1 Madrigal Pharmaceuticals $2,950.00 07/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246613
Principal investigator 1 Madrigal Pharmaceuticals $1,500.00 07/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246617
Principal investigator 1 Madrigal Pharmaceuticals $1,500.00 07/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246621
Principal investigator 1 Madrigal Pharmaceuticals $2,064.82 07/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246473
Principal investigator 1 Tanabe Pharma America, Inc. $500.00 07/04/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870383
Principal investigator 1 Madrigal Pharmaceuticals $19,743.00 07/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246239
Principal investigator 1 Madrigal Pharmaceuticals $810.00 07/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246243
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 07/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870477
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 06/24/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654252
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654254
Principal investigator 1 Tanabe Pharma America, Inc. $500.00 06/24/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870387
Principal investigator 1 Tanabe Pharma America, Inc. $280.00 06/24/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870389
Principal investigator 1 Tanabe Pharma America, Inc. $300.00 06/24/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870391
Principal investigator 1 Tanabe Pharma America, Inc. $427.95 06/24/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870393
Principal investigator 1 Tanabe Pharma America, Inc. $27.00 06/24/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870395
Principal investigator 1 Madrigal Pharmaceuticals $37,800.00 06/19/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245766
Principal investigator 1 Madrigal Pharmaceuticals $809.25 06/19/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245770
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 06/19/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245774
Principal investigator 1 Gilead Sciences, Inc. $5,619.00 06/17/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207040
Principal investigator 1 Madrigal Pharmaceuticals $4,428.67 06/12/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245235
Principal investigator 1 Madrigal Pharmaceuticals $7,687.40 06/12/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245239
Principal investigator 1 Gilead Sciences, Inc. $1,500.00 06/10/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207034
Principal investigator 1 Bausch Health US, LLC $5,744.34 06/05/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842283
Principal investigator 1 Madrigal Pharmaceuticals $2,500.40 06/05/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244841
Principal investigator 1 Gilead Sciences, Inc. $2,075.00 06/03/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207011
Principal investigator 1 Gilead Sciences, Inc. $3,500.00 06/03/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207021
Principal investigator 1 Gilead Sciences, Inc. $1,208.96 06/03/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207028
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 06/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870479
Principal investigator 1 Madrigal Pharmaceuticals $9,938.42 05/28/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244526
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654248
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 05/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654250
Principal investigator 1 Madrigal Pharmaceuticals $4,565.22 05/22/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244087
Principal investigator 1 Madrigal Pharmaceuticals $23,471.16 05/15/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243480
Principal investigator 1 Tanabe Pharma America, Inc. $2,264.40 05/15/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870397
Principal investigator 1 Bausch Health US, LLC $4,588.29 05/07/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842275
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 05/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870481
Principal investigator 1 Gilead Sciences, Inc. $3,849.00 04/22/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229207003
Principal investigator 1 Tanabe Pharma America, Inc. $3,500.00 04/15/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870375
Principal investigator 1 Tanabe Pharma America, Inc. $1,000.00 04/15/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870377
Principal investigator 1 Tanabe Pharma America, Inc. $1,172.47 04/08/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870373
Principal investigator 1 Bausch Health US, LLC $4,595.85 04/01/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842278
Principal investigator 1 Madrigal Pharmaceuticals $9,592.42 04/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241519
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 04/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870471
Principal investigator 1 Gilead Sciences, Inc. $13,738.00 03/18/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206995
Principal investigator 1 Bausch Health US, LLC $3,206.76 03/11/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842266
Principal investigator 1 Madrigal Pharmaceuticals $115,354.00 03/06/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240408
Principal investigator 1 Madrigal Pharmaceuticals $29,935.63 03/06/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240412
Principal investigator 1 Bausch Health US, LLC $105.00 03/05/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842264
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 03/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870493
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654238
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654240
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654242
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654244
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654246
Principal investigator 1 Madrigal Pharmaceuticals $98,260.00 02/20/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239909
Principal investigator 1 Gilead Sciences, Inc. $11,140.00 02/19/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206988
Principal investigator 1 Tanabe Pharma America, Inc. $2,264.40 02/18/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870409
Principal investigator 1 Tanabe Pharma America, Inc. $648.00 02/18/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870411
Principal investigator 1 Tanabe Pharma America, Inc. $54.00 02/18/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870413
Principal investigator 1 Madrigal Pharmaceuticals $5,473.57 02/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239589
Principal investigator 1 Madrigal Pharmaceuticals $26,443.70 02/06/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239250
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 02/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870491
Principal investigator 1 Bausch Health US, LLC $2,509.29 01/28/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842260
Principal investigator 1 Boehringer Ingelheim International GmbH $479.78 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654222
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654224
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654226
Principal investigator 1 Boehringer Ingelheim International GmbH $42.86 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654228
Principal investigator 1 Boehringer Ingelheim International GmbH $6.74 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654230
Principal investigator 1 Boehringer Ingelheim International GmbH $25.72 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654232
Principal investigator 1 Boehringer Ingelheim International GmbH $4.28 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654234
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 01/28/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220654236
Principal investigator 1 Eli Lilly and Company $87,022.00 01/28/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187885820
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 01/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654344
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 01/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654346
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 01/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654348
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 01/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654350
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 01/27/2025 Non-covered Recipient Entity
Kansas City Gastroenterology And Hepatology Physicians Group LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220654352
Principal investigator 1 Tanabe Pharma America, Inc. $2,264.40 01/17/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870407
Principal investigator 1 Eli Lilly and Company $1,329.37 01/15/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187884300
Principal investigator 1 Madrigal Pharmaceuticals $1,354.72 01/10/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238367
Principal investigator 1 Bausch Health US, LLC $1,961.82 01/07/2025 Non-covered Recipient Entity
Kansas City Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842271
Principal investigator 1 Tanabe Pharma America, Inc. $1,586.79 01/07/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870405
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 01/01/2025 Non-covered Recipient Entity
KANSAS CITY RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870489